Every 8-K that Scholar Rock Holding Corporation (SRRK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SRRK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRRK filings page.
Scholar Rock Holding Corporation described an update to its existing at-the-market offering program. The company filed a new prospectus supplement under its shelf registration statement on Form S-3ASR, allowing it to offer and sell, from time to time at its sole discretion through Jefferies LLC as sales agent, additional shares of common stock with an aggregate offering price of up to $200,000,000.
This new prospectus supplement replaces and supersedes the prior prospectus supplement dated November 14, 2025, and the offering pursuant to that prior supplement has been terminated. To date, the company has generated approximately $257.7 million in net proceeds from sales of common stock under the at-the-market program. Legal opinions and related consents from Goodwin Procter LLP are included as exhibits.
Scholar Rock reported a Q2 2026 net loss of $109.9 million, or $0.84 per share, with no revenue for the quarter. Research and development expense was $58.2 million and general and administrative expense was $50.7 million. The company ended June 30, 2026 with $492.1 million in cash, cash equivalents, and marketable securities, reflecting $62.8 million of net proceeds from its at-the-market equity program.
The company highlighted regulatory progress for its lead SMA candidate apitegromab. Its Biologics License Application is under FDA review with a September 30, 2026 PDUFA date, supported by two fill-finish facilities and what the company describes as ample commercial supply upon approval. The EMA is reviewing a Marketing Authorisation Application and is awaiting FDA inspection classification of the Catalent Indiana facility, while Scholar Rock discusses adding a second fill-finish site. The U.S. commercial team is preparing for launch, and development continues in earlier-stage programs, including the Phase 2 OPAL trial in infants and toddlers with SMA, the newly initiated Phase 2 FORGE trial in FSHD, and a Phase 1 study of SRK-439 in healthy volunteers.
Scholar Rock Holding Corporation reported the results of its annual stockholder meeting held on June 4, 2026. Stockholders elected four Class II directors—David Hallal, Kristina Burow, Michael Gilman, Ph.D., and Katie Peng—to three-year terms ending at the 2029 annual meeting.
Support for these directors ranged from 86,753,433 to 96,269,103 votes in favor, with 14,598,794 to 24,114,464 votes withheld. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 113,411,438 votes for, 764,548 against, and 500,031 abstentions.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, with 68,280,961 votes for, 42,455,921 against, and 131,015 abstentions. These outcomes confirm continued stockholder approval of the Company’s board composition, auditor selection, and executive pay program.
Scholar Rock Holding Corporation furnished an update on its financial and operating results for the quarter ended March 31, 2026. The company issued a press release, provided as Exhibit 99.1, and prepared a corporate presentation, furnished as Exhibit 99.2, in connection with these results.
The slides are being used during a conference call scheduled for 8:00 am ET on May 7, 2026 to discuss the quarter and provide a business update. The press release and slides are designated as furnished, not filed, under the Exchange Act, limiting their use for certain legal purposes.
Scholar Rock Holding Corporation filed a current report describing that it has resubmitted its Biologics License Application (BLA) to the FDA for apitegromab, a muscle-targeted therapy for children and adults with spinal muscular atrophy (SMA).
The company anticipates FDA acceptance of the resubmitted BLA within 30 days and a review period of up to six months, with a PDUFA action date expected in late September 2026. The resubmission also adds a second U.S. fill-finish facility alongside Catalent Indiana to support the apitegromab supply chain and planned global commercial demand. In Europe, the EMA review of the apitegromab Marketing Authorisation Application is progressing, with a decision anticipated around mid-2026.
Scholar Rock Holding Corporation filed an amended report to correct a scrivener’s error in its prior earnings release, updating net loss per share and weighted average shares outstanding for the quarter ended December 31, 2025.
For that quarter, the company reported a net loss of $91.0 million, or $0.76 per share, compared with a net loss of $66.5 million, or $0.61 per share, a year earlier. For full year 2025, net loss was $377.9 million, or $3.29 per share, versus $246.3 million, or $2.47 per share, in 2024. Scholar Rock highlighted progress on apitegromab for spinal muscular atrophy, noting it is ready to resubmit its BLA after FDA reinspection of Novo Nordisk’s Catalent Indiana facility, and described a new multi‑tranche financing with Blue Owl Capital, including an initial $100 million used to retire its prior Oxford Finance debt and additional tranches tied to future milestones and approvals.
Scholar Rock Holding Corporation reported wider losses for the fourth quarter and full year 2025 while highlighting progress in its spinal muscular atrophy pipeline. Quarterly net loss was $90.965 million, compared with $66.454 million a year earlier, and full-year net loss was $377.939 million versus $246.294 million in 2024.
Operating expenses rose sharply, with 2025 research and development at $208.440 million and general and administrative at $176.205 million. Cash, cash equivalents and marketable securities totaled $367.563 million as of December 31, 2025, down from $437.278 million a year earlier.
The company emphasized advancing apitegromab for SMA, citing FDA engagement and readiness to resubmit its BLA after successful reinspection of Novo Nordisk’s Catalent Indiana facility. It also highlighted SRK-439, a preclinical myostatin inhibitor, and described 2026 as potentially “transformative” as it continues to invest heavily in its neuromuscular disease portfolio.
Scholar Rock Holding Corporation reported preliminary financial and business updates, including an estimated unaudited cash, cash equivalents and marketable securities balance of approximately $365 million as of December 31, 2025. The company has not yet finalized its full fourth-quarter and full-year 2025 results, and the ongoing audit could change these preliminary figures.
The company also issued a press release with business updates and more detail on its 2026 strategic priorities, furnished as Exhibit 99.1, and prepared a corporate presentation for meetings at the 44th Annual J.P. Morgan Healthcare Conference, filed as Exhibit 99.2. The update includes forward-looking statements about its growth strategy, clinical programs, regulatory timelines, commercial launch expectations, a cash runway into 2027, and other operational milestones, all subject to risks outlined in its most recent quarterly report.
Scholar Rock Holding Corporation announced it filed a prospectus supplement for its at-the-market offering program, permitting the offer and sale, from time to time at its sole discretion, of additional shares of common stock with an aggregate offering price of up to $200,000,000. Sales will be conducted through Jefferies LLC as sales agent under the company’s automatically effective shelf registration statement on Form S-3ASR.
Offerings of these shares will be made only by means of the prospectus supplement and the base prospectus. The company also filed a legal opinion from Goodwin Procter LLP as an exhibit. This update provides ongoing access to equity capital via an established ATM facility, allowing the company to sell small amounts of stock into the market as conditions permit.
Scholar Rock Holding Corporation (SRRK) furnished an update regarding its quarterly results process. The company issued a press release with financial and operating results for the quarter ended September 30, 2025, furnished as Exhibit 99.1.
It also furnished presentation slides as Exhibit 99.2 for a conference call scheduled for 8:00 am ET on November 14, 2025. The press release and slides are furnished, not filed, under the Exchange Act.
Scholar Rock (SRRK) reported an update under Other Events. On October 10, 2025, the company was informed by Novo Nordisk that the U.S. Food and Drug Administration has classified the Catalent Indiana, LLC facility as “official action indicated.”
The classification follows a Form FDA 483 issued to Catalent Indiana, LLC on July 14, 2025. The filing does not provide additional details or actions beyond noting the FDA’s inspection outcome.
Scholar Rock Holding Corporation reported that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its Biologics License Application for apitegromab, a treatment candidate for spinal muscular atrophy (SMA). The company disclosed that it announced the CRL in a press release dated September 23, 2025, which is furnished as an exhibit. A CRL means the FDA has completed its review of the application and, instead of approving it in its current form, has provided feedback that must be addressed before approval can be granted.